Tesamorelin + Ipamorelin

Overview

Pre-mixed blend of Tesamorelin (a stabilized GHRH(1-44) analog) and Ipamorelin (a selective ghrelin-receptor agonist). Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy; Ipamorelin is not FDA-approved. The blend itself is NOT clinically validated — no controlled trial has tested Tesamorelin co-administered with Ipamorelin. Evidence is inferred from the individual components.

Mechanism of Action

Tesamorelin binds the pituitary GHRH receptor (Falutz et al., NEJM 2007, demonstrated GH/IGF-1 elevation and visceral fat reduction as monotherapy). Ipamorelin selectively activates GHS-R1a without meaningful cortisol/prolactin elevation (Raun et al., 1998). The broader pharmacological principle of GHRH + GHRP synergy for pulsatile GH amplification is established with other pairs (Veldhuis & Bowers, 2009), but has not been demonstrated for this specific combination.

Research Summary

Tesamorelin has Phase 3 monotherapy data in HIV-associated visceral adiposity. There is no published human trial of Tesamorelin + Ipamorelin co-administration. The blend is a vendor formulation, not a clinically validated protocol.

Dosing Information

Reported Side Effects

• See individual compound profiles for Tesamorelin and Ipamorelin

Research References

• Falutz J, et al. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. (2007)
• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. (1998)
• Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085-E1092. (2009)